S. Korea cautious against dexamethasone's efficacy against new coronavirus
SEOUL, June 17 (Yonhap) -- South Korean health authorities on Wednesday cautioned against the efficacy of dexamethasone in treating the novel coronavirus, saying the widely used steroid should only be used as a supplementary treatment against COVID-19.
"Dexamethasone is a drug that reduces inflammation and does not fundamentally treat COVID-19," Jeong Eun-kyeong, head of the Korea Centers for Disease Control and Prevention (KCDC), said during a daily briefing.
The remarks came after scientists at the University of Oxford announced that dexamethasone reduces the risk of death in seriously ill COVID-19 patients by about 33 percent.
The World Health Organization also said dexamethasone is the first treatment to be shown to reduce mortality in virus patients requiring oxygen or ventilator support.
"We think dexamethasone is not a drug that is as effective as other treatments (such as remdesivir) but is a sort of supplementary treatment," Jeong said.
The KCDC also cautioned against possible side effects, noting that other steroids have previously been used to reduce inflammation in COVID-19 patients.
The country's drug watchdog, the Ministry of Food and Drug Safety, has so far approved the use of 79 dexamethasone-based drugs.
khj@yna.co.kr
(END)
-
BTS fails to win Grammy for 3rd consecutive year
-
(LEAD) 1st S. Korean state compensation ordered for victim of Vietnam War mass killings
-
Jay Park's Won Soju to be sold in U.S.
-
(2nd LD) Search under way for 9 missing after fishing boat capsizes
-
(LEAD) Ahn calls off campaigning activities amid row with Yoon's office
-
S. Korea opens metaverse platform for Korean-language learning
-
(LEAD) N. Korean leader visits barracks with his daughter to mark army founding anniv.
-
N. Korea holds military parade in Pyongyang to mark armed forces' founding anniv.: source
-
Ex-gov't employee summarily indicted for alleged attempt to sell Jungkook's lost hat
-
S. Korea to hold nationwide civil air defense drills in May after 6-year hiatus